METTL1-mediated m7G tRNA modification enhances the translation of EGFR, thereby promoting the proliferative ability of HCC cells and inhibiting apoptosis to maintain resistance to lenvatinib in HCC [43]. The gene discussed is EGFR; the disease is hepatocellular carcinoma.